MMP2 and prostate cancer: In accordance, we previously indicated that aprepitant reduces the migratory phenotype of different tumor types including esophageal squamous cell carcinoma [41], cervical cancer, [23], and prostate cancer [22] which was correlated with reduced expression of MMP-2 and MMP-9.